HLI Bags $39.8m to Advance AI-driven Health Risk Analysis Platform nextdigitalhealth.com

Human Longevity, Inc. (HLI), a San Francisco-based precision medicine company, has raised $39.8M in a series B funding round to advance its AI-driven health risk insight and recommendation platform. The new capital will also allow the company to introduce new longevity-focused technologies and services.

Co-founded in 2013 by Dr J Craig Venter, a genomic pioneer, the company focuses on leveraging innovative technologies to extend human health and well-being beyond the traditional treatment approach, which focuses only on treating diseases.